Top

Published in:

01-10-2009 | Original Article

The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study

Authors: Franck Zenasni, Marion Botella, Dominique Elias, Sarah Dauchy, Valérie Boige, David Malka, Michel Ducreux, Jean-Pierre Pignon, Diane Goéré, Marc Pocard

Published in: Supportive Care in Cancer | Issue 10/2009

Abstract

Background

Hyperthermic intraperitoneal chemotherapy (HIPEC) after complete surgical resection is currently accepted as a therapeutic option for peritoneal carcinomatosis. However, considerable morbidity is reported after HIPEC.

Objective

We aimed to evaluate the impact of HIPEC on the quality of life (QoL) of survivors without recurrences of disease according to socio-demographic and medical variables. For that purpose, HIPEC was used as a global concept including the surgical procedure effects.

Materials and methods

A cross-sectional study was performed by analyzing questionnaires concerning socio-demographic data, the psychological status, and general and specific QoL scores.

Results

Sixty-eight patients (86% of those contacted) completed and returned mailed questionnaires. For 19/21 QoL dimensions explored, survivors reported good to very good QoL with a median score ≥67%. The two adversely affected dimensions were future prospects and sexual functioning with a mean score of 57% and 23%, respectively. The burden of carcinomatosis, evaluated by a peritoneal index, was not correlated with statistically identified sequels in QoL. The extent of morbidity due to HIPEC, evaluated by the hospital stay, was statistically correlated with only one score, namely, embarrassment during social activities (p = 0.01) but not during familial life.

Conclusions

Even though HIPEC is considered as an aggressive treatment, survivors reported good to very good QoL. However, specific care for the psychological aspect, as reflected by anxiety regarding future prospects and sexual activity, needs to be developed for survivors.

The present study was conducted in 2006 and all data were analyzed during 2007.

Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi institutional study. J Clin Oncol 22:3284–3294. doi:10.1200/JCO.2004.10.012 PubMedCrossRef

Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA (2004) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomicyn C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 11:178–186. doi:10.1245/ASO.2004.05.009 PubMedCrossRef

Verwaal VJ, Tinteren HV, Ruth SV, Zoetmulder FAN (2004) Prediciting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91:739–746. doi:10.1002/bjs.4516 PubMedCrossRef

Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V, Ducreux M (2004) Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 15:1558–1565. doi:10.1093/annonc/mdh398 PubMedCrossRef

Glehen O, Mohamed F, Gilly FN (2004) Digestive peritoneal carcinomatosis: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5:219–228. doi:10.1016/S1470-2045(04)01425-1 PubMedCrossRef

Elias D, Pocard M, Sideris L, Edè C, Ducreux M, Boige V, Lasser P (2004) Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin. Br J Surg 91:455–456. doi:10.1002/bjs.4399 PubMedCrossRef

Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D, Pocard M (2005) Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 90:220–225. doi:10.1002/jso.20253 PubMedCrossRef

Pocard M, Boige V (2005) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal colorectal carcinomatosis: a newly validated standard whose contribution remains to be assessed. Bull Cancer 92:151–154PubMed

McQuellon RP, Loggie BW, Fleming RA et al (2001) Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Clin Oncol 27:65–73

10.

McQuellon RP, Danhauer SC, Russell GB et al (2007) Monitoring outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatis. Ann Surg Oncol 14:1105–1113. doi:10.1245/s10434-006-9304-5 PubMedCrossRef

11.

Tuttle TM, Zhang Y, Greeno E et al (2006) Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 13:1627–1632. doi:10.1245/s10434-006-9186-6 PubMedCrossRef

12.

McQuellon RP, Logie BW, Lehman AB et al (2003) Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 10:155–162. doi:10.1245/ASO.2003.03.067 PubMedCrossRef

13.

Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P (2005) Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 31:53–58. doi:10.1016/j.ejso.2004.09.011 PubMedCrossRef

14.

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. doi:10.1093/jnci/85.5.365 PubMedCrossRef

15.

Sprangers MAG, te Velde A, Aaronson NK (1999) The construction and testing of the EORTC colorectal cancer-specific Quality of Life Questionnaire Module (QLQ-CR38). Eur J Cancer 35:238–247. doi:10.1016/S0959-8049(98)00357-8 PubMedCrossRef

16.

Fayers PM, Aaronson NK, Bjordal K et al (2001) EORTC quality of life group. The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels

17.

Shibata D, Guillem JG, Lanouette N et al (2000) Functional and quality-of-life outcomes in patients with rectal cancer after combined modality therapy, intraoperative radiation therapy, and sphincter preservation. Dis Colon Rectum 43:752–758. doi:10.1007/BF02238009 PubMedCrossRef

18.

Sideris L, Zenasni F, Vernerey D, Dauchy S, Lasser P, Pignon JP, Elias D, Di Palma M, Pocard M (2005) Quality of life of patients operated on for low rectal cancer: impact of the type of surgery and patients’ characteristics. Dis Colon Rectum 48:2180–2191. doi:10.1007/s10350-005-0155-0 PubMedCrossRef

19.

Cayrou S, Dickes P, Gauvain-Picard A, Dolbeault S, Callahan S, Roge B (2000) Validation of the French translation of the “Profile of mood states”. Psychologie et psychométrie 21:5–22

20.

McNair D, Lorr M, Droppleman L (1971) Profile of mood states. Education and Industrial Testing Service, San Diego

21.

Curran D, Aaronson N, Standaert B et al (2000) Summary measures and statistics in the analysis of quality of life data: an example from an EORTC–NCIC–SAKK locally advanced breast cancer study. Eur J Cancer 36:834–844. doi:10.1016/S0959-8049(00)00056-3 PubMedCrossRef

22.

Eveno C, Zenasni F, Dagois S, Mateo J, Boschetto A, Pocard M (2008) Morbidity, mortality and quality of life related to HIPEC: review of the literature concerning short and long term risks. In: Elias D, Glehen O, Gilly F (eds) Peritoneal carcinomatosis of gastrointestinal origin and primitive. Rueil-Malmaison, Arnette, pp 61–68

Title: The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study
Authors: Franck Zenasni
Marion Botella
Dominique Elias
Sarah Dauchy
Valérie Boige
David Malka
Michel Ducreux
Jean-Pierre Pignon
Diane Goéré
Marc Pocard
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 10/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0578-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objective

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2009

Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial

Strength of skeletal muscle and quality of life in patients suffering from “typical male” carcinomas

Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid

Upper gastrointestinal symptoms in patients with advanced cancer: relationship to nutritional and performance status

Effects of nutritional and psychological status of the patients with advanced stomach cancer on physical performance status

‘Quite an awkward situation to be in’: perceptions of patients, carers and health and social care professionals of the supportive cancer care in British military personnel stationed in Germany

Keynote webinar | Spotlight on antibody–drug conjugates in cancer